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performed by Mexican private consultants and 67.6% of the CEE presentations used
a decision tree-model or a Markov model. CONCLUSIONS: An increase of Mexican 
presentations at ISPOR meetings mainly promoted by local consultants and pharma-
ceutical companies with a medium methodological quality.
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THE STATUS QUO OF THE USAGE OF CHINESE VERSIONS OF
GENERIC HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS
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OBJECTIVES: In order to assess health-related quality of life (HRQoL) among
Chinese-speaking populations, a number of HRQoL instruments originally developed
in English in North America or Europe were translated into Chinese over the past two
decades. The current study attempted to review the usage of Chinese versions of 
generic HRQoL instruments including SF-36, SF-12, SF-8, SF-6D, EQ-5D, HUI2,
HUI3, and QWB. METHODS: MEDLINE and ﬁ ve Chinese databases including CNKI 
(mainland China), CBM (mainland China), Wanfang (mainland China), CEPS
(Taiwan), and HKInChiP (Hong Kong & Macau) were searched up to December 2008
for HRQoL studies in Chinese-speaking populations. RESULTS: A total of 1341 rel-
evant original research papers were identiﬁ ed. Approximately three-quarters (73.90%)
of papers were published in Chinese journals. The vast majority of papers (91.50%) 
were published after the year of 2002. In terms of the number of papers, the top three
frequently used generic HRQoL instruments were SF-36 (n  1281), EQ-5D (n  30),
and SF-12 (n  28). One thousand and sixty-two papers reported HRQoL measured
in patient populations, with circulatory diseases being the most frequently studied 
therapeutic areas (n  195). Geographically, identiﬁ ed studies were mainly conducted 
in mainland China (n  1012), followed by Taiwan (n  149), Hong Kong (n  112), 
Singapore (n  53), U.S. (n  10), Canada (n  4) and Australia (n  1). Except for 
Singapore where the majority of studies were used to evaluate instruments, generic 
HRQoL instruments were mainly used to measure quality of life in other countries or 
districts. CONCLUSIONS: There is a growing body of English and Chinese literature 
on the measurement of HRQoL using generic HRQoL instruments in Chinese-
speaking populations. For better assessment of Chinese-speaking populations, the
appropriateness of existing generic HRQoL instruments should be further evaluated
in the future.
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OBJECTIVES: To develop process indicators for assessing the quality of care in the
23 Primary Care Groups (PCGs) of the Local Health Unit (LHU) of Reggio Emilia,
Italy, using administrative data. METHODS: Data were extracted from the 2006 
Reggio Emilia LHU Healthcare database, including demographic, hospital, outpatient 
pharmacy, and outpatient specialty data on all residents, as well as information about 
each LHU General Practitioner (GP). We retrieved information on approximately
450,000 LHU residents and on 343 GPs and their PCG of practice. We included GPs
who practiced for the whole year in only one PCG. The sample patient population
comprised individuals who were residents in the LHU for the whole year and did
not change their GP during the year. Initially developed based on a literature review,
the quality indicators were deﬁ ned jointly by the project team and leaders of the 23
PCGs. For each indicator, we computed the proportion of eligible patients within each 
PCG who received the recommended care. RESULTS: A total of 340 GPs (99.1%)
met the inclusion criteria. These GPs had a total number of 383,772 continuously 
enrolled patients for 2006. The number of GPs per PCG ranged from 4 to 28 and the
number of patients per PCG varied from 3,862 to 30,855. Nine quality care indicators
covering cardiovascular, diabetes, and asthma management were identiﬁ ed. Analyses 
of the indicators exhibited signiﬁ cant variation among the PCGs. For example, the
proportion of post-myocardial infarction patients receiving beta-blockers varied from 
33.3% to 90.9% across the PCGs. CONCLUSIONS: Quality of care provided by
Italy’s family physician practices can be assessed using administrative data. For the
indicators adopted, study ﬁ ndings showed a considerable variation in medical patterns 
among PCGs. These results provide LHU policy makers and PCGs with relevant
information to establish quality improvement initiatives targeted at the individual 
practice level.
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OBJECTIVES: The purpose of the study was to measure the extent of pharmacoeco-
nomics education (PE) in non-US colleges of pharmacy. METHODS: Two surveys
were used. Survey 1 was e-mailed or faxed to over 700 colleges of pharmacy, obtained 
from the International Pharmaceutical Federation Website or through Medline and
Google Searches, asking respondents if pharmacoeconomics was taught in their 
college. Survey 2 was sent to respondents who taught PE asking: 1) number of class-
room hours devoted to PE 2) whether these were in a required or elective course 3)
number of students in the course 4) topics covered 5) resources (books/articles) used.
RESULTS: Ninety-eight schools responded to Survey 1. Pharmacoeconomics educa-
tion was offered at 62 (63%) of these 98 colleges. The response rate for Survey 2 was 
52% (n  33). However 3 colleges did not provide complete data, leaving data on 30
colleges for this analysis. Twenty-six (87%) colleges indicated that pharmacoeconom-
ics was taught as a required course, 2 (7%) indicated that it was offered as an elective 
course, and 2 (7%) indicated that PE was taught as both a required and elective course. 
The median number of required hours was 16 (std dev  150). The number of elective 
hours ranged from 3 to 45 with a median of 27 (std dev  19). The mean number of 
students taking pharmacoeconomics as a required course was 104 (std dev  60; 
median  90, range 12–250). “Types of pharmacoeconomic analyses” (i.e., comparing
CBA, CEA, CMA, CUA) was the most common topic taught. Several articles and 
books were provided as resources. A comparison of these results to similar studies
conducted previously will be provided. CONCLUSIONS: Correct and current contact 
information for international pharmacy schools was difﬁ cult to obtain, and obtaining 
high response rates was also challenging. In this study, both e-mails and facsimiles
were used to increase response rates.
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OBJECTIVES: To explore the present the process followed to implement technologies 
in the public health sector from the perspective of key decision makers. The Spanish
National Health System (NHS) is decentralized, and most management is decided in
the seventeen Autonomous Communities (AC). Several health technology evaluation
agencies (HTEA) have been established countrywide. The literature shows that 
im plementation ‘technologies’ remains far from ideal in Spain (Gonzalez B, 2007).
METHODS: A naturalistic, qualitative study was conducted. Semi-structured inter-
views with key decision makers across country, including senior health managers at
the Autonomous Communities’ Departments of Health (macro-level of decision), 
Hospitals’ managers and directors (meso-level), Heads of clinical services (micro-level 
of decision), and experts on health services’ research and evaluation were carried out 
to explore their views on the present of the implementation of technologies in the 
health system. Data interviews data were collected until different categories of infor-
mation was saturated. The grounded theory method was applied to categorize the 
information gathered. RESULTS: A total of 35 interviews were conducted, including 
managers, researchers and evaluators. Eight categories of information emerged: 1) the 
industry’s inputs to the NHS, contributing to its modernization; 2) the assessment of 
technologies, based on safety and efﬁ cacy while leaving behind effectiveness, efﬁ ciency 
or cost-beneﬁ t; 3) implementation processes, relying on informal mechanisms and 
variable criteria; 4) the gap, between legal statements and existing practices; 5) HTEA 
reports’, of scarce impact on managers’ decisions; 6) ﬁ nancing mechanisms, that one 
barely effective in responding to technological progresses; 7) the industry, seen as a 
self-centered NHS provider making little efforts to realistically show the “pros and
cons” of technologies; 8) the need for transparency, openness and consensus amongst
all involved. CONCLUSIONS: Major opportunities for improvement in the imple-
mentation of technologies in the NHS exist. These ﬁ ndings set the basis for exploring
strategies to enhance the future scenario.
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OBJECTIVES: The quality of evidence used by manufacturers in submissions to HTA 
agencies is an important determinant of a positive appraisal. In 2008, NICE revised 
guidelines and added a section on indirect synthesis methods. The study objective was 
to evaluate previous trends and understand past and evolving inﬂ uences of method-
ological factors, particularly indirect and mixed treatment comparisons, on submission 
outcome. METHODS: A landscape review was conducted of NICE submission meth-
odologies and appraisal outcome, with focus on the use of indirect comparison. Key 
data were extracted from NICE/ ERG documents for all NICE appraisals (2003-
August 2008). Also, case studies were investigated in rheumatoid arthritis, osteopo-
rosis, bone metastases and oncology. Key ﬁ ndings and recommendations for submission 
preparation, with focus on indirect comparison use, are presented. RESULTS: The 
number of indirect comparisons used in appraisals has increased from 2 to 8 between
2005 and 2008. The proportions of published NICE appraisals mentioning indirect 
comparisons to total appraisals were 2/7 (2005), 2/18 (2006), 7/21 (2007) and August 
2/18 to August 2008. Indirect comparison, historically, used primarily in oncology, is 
increasingly being implemented in other therapeutic areas. However, 81% of NICE 
submissions that included indirect comparison have been recommended, compared 
with 86% that did not include indirect comparison. NICE critique of indirect com-
parisons across submissions focused on the lack of clear justiﬁ cation of methodology,
assumptions, and comparators used, along with management of clinical and statistical 
heterogeneity. Further, case studies have shown the need to avoid non-validated 
methods and distant indirect comparisons. CONCLUSIONS: Where head-to-head 
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data are unavailable or insufﬁ cient, indirect comparison is increasingly used across 
therapy areas, reﬂ ected by recent NICE guidance. To maximise quality of submissions, 
analyses must use validated methodology, manage heterogeneity appropriately and
clearly justify decisions and usage of methods and comparators. Rationale for use of 
indirect comparisons is also required.
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OBJECTIVES: To explore key decision-makers’ agreement on desirable scenarios to
effectively implement health technologies in the public sector in the future. From 2006 
onwards, the Spanish government has undertaken several initiatives to establish a 
reliable mechanism for implementing technologies in the National Health System 
(NHS). METHODS: A naturalistic, qualitative, two phases study was conducted. The 
current situation of implementing health technologies’ in Spain was explored on an 
earlier study. Based on the present circumstances, both phases of this study sought to 
explore and determine the level of agreement amongst key decision- makers on suitable 
strategies to improve the existing conditions. Phase One: semi-structured interviews
explored their views on desirable scenarios to more effectively implement health
technologies in the public sector. Phase Two: the Delphi method determined the level
of agreement amongst participants on key messages consistently endorsed during the
interviews. Two rounds of questionnaires were required to consolidate consensus level.
RESULTS: A total of 35 interviews were conducted, including managers, researchers 
and evaluators across country. Several categories of information emerged and were 
assessed in the Delphi process amongst 26 participants. Most responses (q75%) agreed
on: 1) decision making: based on a demonstrated incremental cost-beneﬁ t ratio; 2) 
desirable attributes: efﬁ ciency and cost-beneﬁ t, safety and eﬁ cacy; 3) uniﬁ ed processes 
countrywide; 4) information: open and consistent management across, and within,
levels of decision, with the health technology evaluation agencies (HTEA), and the 
industry; 5) education: continued training of decision- makers; 6) evaluation model: 
organized HTEA, coordinating efforts, following up transparent, participative and
methodologically robust processes agreed across Europe; 7) ﬁ nancing mechanisms: 
more ﬂ exible, collaborative formulas to avoid blocking the implementation of cost-
beneﬁ cial technologies; and 8) the industry’s role: expert, legitimate provider, “trainer 
of trainees” CONCLUSIONS: These ﬁ ndings should serve the Spanish Health Author-
ities to effectively improve the implementation of health technologies in the NHS.
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A COMPARISON OF REASONS FOR RECOMMENDATION AND
REJECTION ACROSS FOUR HEALTH TECHNOLOGY APPRAISAL
SYSTEMS CATEGORISED BY DISEASE
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Heron Evidence Development Ltd, Luton, UK
OBJECTIVES: Reasons provided by the health technology appraisal (HTA) agencies 
for the guidance issued vary across the board. Following interest from a previous 
ISPOR presentation, we sought to further investigate the reasons for recommenda-
tion/rejection between NICE, SMC, CADTH, and PBAC with a speciﬁ c focus on
disease-speciﬁ c reasons. METHODS: A previously developed database was updated 
with data from submissions appraised between 31 May and 31 December 2008 by 
NICE, SMC, CADTH, and PBAC, in England/Wales, Scotland, Canada, and Australia,
respectively. Submissions with opposing decision outcomes were included and were
categorised by disease based on the BNF (cardiovascular system, CNS, endocrine
system, gastro-intestinal system, infections, malignant diseases and immunosuppres-
sion, musculoskeletal and joint diseases, nutrition and blood, obstetrics, gynaecology, 
and urinary tract disorders, respiratory system, and skin). Reasons for acceptance/
rejection were analysed across the disease categories. RESULTS: In total, 83 submis-
sions were included for analysis. Across all HTAs, the most common rejection reasons 
for skin disease interventions included “not more effective than comparators” and 
“not cost-effective”; these reasons were demonstrated in 100% of the submissions for
interventions relating to skin disorders. The most common rejection reasons in malig-
nant diseases and immunosuppression included “not cost-effective” and “concerns
over the economic model” (100% for both). The majority of the reasons for rejection
were reported in 50% or less of the submissions per disease group. Of the recom-
mended interventions, those for the treatment of skin disease were all “more effective
than placebo and comparators” as well as having a lower cost. Interventions for 
infectious diseases and obstetrics, gynaecology, and urinary tract disorders demon-
strated a wide range of reasons for rejection. CONCLUSIONS: Sub-group analysis 
categorised by disease provides further insight into the primary reasons for rejection 
and recommendation across HTA bodies. Analysing trends within these submissions
highlights potential obstacles for new interventions within a speciﬁ c disease area.
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REVIEW OF HTA RECOMMENDATIONS FOR DRUG THERAPIES IN 
POLAND ISSUED FROM SEPTEMBER 6, 2007 UNTIL OCTOBER 28, 
2008 BY THE CONSULTATIVE COUNCIL (APPRAISAL COMMITTEE) 
OF AHTAPOL IN POLAND
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OBJECTIVES: Review of HTA recommendations issued by the Consultative Council 
of AHTAPol in Poland. METHODS: Fifty-nine drug recommendations, January 
2007–58/16/2008, from September 2007 until October 2008, available online, were 
analyzed. Appraisals were grouped into positive and negative recommendations. The 
clinical and non-clinical reasons for rejection of use were studied. The positive guid-
ances were divided into recommendations with major, minor and without restrictions. 
RESULTS: Thirty-two HTA reports received negative recommendations; 26 on the 
grounds of clinical evidence and 6 because of non-clinical issues. Among 26 recom-
mendations, insufﬁ cient clinical effectiveness data was the most frequently stated
reason (18 cases). In other eight guidances, the argument of poor efﬁ cacy or safety 
was raised. Among non-clinical aspects, unacceptable cost-effectiveness ratio was 
given four times. The unacceptable budget impact and risk of off-label use were men-
tioned each one only once. Twenty-seven HTA reports received positive recommenda-
tions, of which 18 for use with major restrictions, 7 with minor restrictions and 2 
without additional restrictions. Among those 18 recommendations, several restrictions
were imposed simultaneously. The most common was prescription restricted to speciﬁ c
subpopulations (15 cases), followed by the need for an improvement of cost-effective-
ness (6 cases), use as second line (5 cases), use if intolerant to other treatment (3 cases), 
reimbursement within speciﬁ c period (2 cases). Among recommendations with minor 
restrictions, lowering price was mentioned ﬁ ve times and use by specialist twice. The 
appraisal of cost-effectiveness analysis was included more frequently in positive rather 
than negative quidances; 63% vs. 57%. The study revealed that an ICER was above 
WHO threshold, accepted by AHTAPoL, in 65% of positive recommendations. An 
ICER was below threshold in 44% of negative recommendations. CONCLUSIONS:
The negative and positive HTA guidances with major restrictions prevailed in Poland. 
Clinical rather than pharmacoeconomic aspects were the most common reason for an 
appraisal recommendation.
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OBJECTIVES: Budget impact analyses (BIAs), along with cost-effectiveness analyses, 
are an essential part of a comprehensive economic assessment of a new health technol-
ogy and increasingly required by national regulatory agencies and managed care
organizations. This study describes the characteristics and growth of BIAs published
in the literature over the past 5–6 years. METHODS: An initial search was conducted
using PubMed, a service of the U.S. National Library of Medicine. Approximately 
800 citations were retrieved using key words of “budget impact” and “budget analy-
sis” and limits of “English Language” and “published within the last 6 years”. Addi-
tional articles were obtained through ancestral and related article searches. All relevant 
BIA articles were identiﬁ ed through an initial title review and secondary abstract
review and included in this study. RESULTS: We identiﬁ ed 32 BIAs published between 
2003 and 2008. The number of studies published each year were 1 (2003), 3 (2004),
5 (2005), 6 (2006), 7 (2007) and 10 (2008), showing a steady upward trend. The
publishing journals had impact factors ranging from 1.985 to 5.888. Just over half of 
published studies (18/32) assessed budget impact of a health technology in the United 
States, while the remaining studies were performed in European countries, Canada 
and Brazil. Although the majority of published BIAs (22/32) examined budget impact
of a speciﬁ c drug, several studies assessed budget impact of various procedures e.g.
surgical, endoscopic. Fourteen (44%) of the published BIAs were performed in
conjunction with a cost-effectiveness analysis. CONCLUSIONS: Despite increased 
demand for and recent growth in number of published BIAs, the absolute number of 
BIA studies published in peer-reviewed journals remains limited. Future studies should
examine whether the quality of published BIAs has improved over time and examine 
changes in practices following the recently published recommendations of the ISPOR
Task Force on good research practices for BIAs.
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THE IMPACT OF THE SUBMISSION SEQUENCE – WHICH APPRAISING
BODY TO SUBMIT TO FIRST?
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OBJECTIVES: The outcomes of health technology assessment (HTA) appraisals con-
ducted by appraising bodies vary greatly and are inﬂ uenced by a range of factors. The 
aim of this research was to determine whether the sequence of agencies in which HTAs
are submitted has an impact on the guidance issued. METHODS: Data from submis-
sions to NICE, SMC and CADTH between 1 November 2005 and 31 December 2008
were included. Only interventions appraised by at least two agencies were of interest.
Extracted information included the name of the intervention, the guidance issued and
the date of guidance. In addition, a correlation between the sequence of submission 
and guidance issued was assessed. RESULTS: A total of 46 interventions were submit-
ted to at least two appraising bodies. In 76% of cases, the ﬁ rst body to conduct
appraisals was the SMC. In contrast, only 4% of the submissions were submitted to
